Intravesical glycosaminoglycans in the management of chronic cystitis

Minerva Urologica e Nefrologica

Volumn 65, Issue 4, 2013, Pages 249-262

  Iacovelli, V ^a   Topazio, L ^a   Gaziev, G ^a   Bove, P ^a   Vespasiani, G ^a   Finazzi Agro E ^a  

^a UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Administration, intravesical; Cystitis, interstitial; Glycosaminoglycans; Urinary tract infections

Indexed keywords

CHONDROITIN SULFATE; DERMATAN SULFATE; GLYCOSAMINOGLYCAN; HEPARAN SULFATE;

CHEMOTHERAPY; CHRONIC CYSTITIS; CYSTALGIA; CYSTITIS; HEMORRHAGIC CYSTITIS; HUMAN; IMMUNOCHEMOTHERAPY; IMMUNOTHERAPY; INTERSTITIAL CYSTITIS; OVERACTIVE BLADDER; RADIOTHERAPY; RECURRENT INFECTION; REVIEW; URINARY TRACT INFECTION;

ADMINISTRATION, INTRAVESICAL; CHRONIC DISEASE; CYSTITIS; CYSTITIS, INTERSTITIAL; GLYCOSAMINOGLYCANS; HUMANS; IMMUNOTHERAPY; RADIATION INJURIES; RECURRENCE; URINARY TRACT INFECTIONS;

EID: 84891409169     PISSN: 03932249     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (60)

1. Parsons CL, Greenspan C, Mulholland SG. The primary antibacterial defense mechanism of the bladder. Invest Urol 1975;13:72-8.
2. Parsons CL, Stauffer CW, Schmidt JD. Reversible inactivation of bladder surface glycosaminoglycan antibacterial activity by protamine sulfate. Infect Immun 1988;56:1341-3.
3. Hurst RE, Zebrowski R. Identification of proteoglycans present at high density on bovine and human bladder luminal surface. J Urol 1994;152:1641-5.
4. Parsons CL. The role of the urinary epithelium in the pathogenesis of interstitial cystitis/prostatitis/urethritis. Urology 2007;69(4 Suppl):9-16.
5. Madersbacher H, van Ophoven A, van Kerrebroeck PE. GAG layer replenishment therapy for chronic forms of cystitis with intravesical glycosaminoglycans - a review. Neurourol Urodyn 2013;32:9-18.
6. Iavazzo C, Athanasiou S, Pitsouni E, Falagas ME. Hyaluronic acid: an effective alternative treatment of interstitial cystitis, recurrent urinary tract infections, and hemorrhagic cystitis? Eur Urol 2007;51:1534-41. (Pubitemid 46634772)
7. Geppetti P, Nassini R, Materazzi S, Benemei S. The concept of neurogenic inflammation. BJU Int 2008;101(Suppl. 3):2-6. (Pubitemid 351328798)
8. Kurth KH, Parsons CL. The interstitial cystitis syndrome: intravesical and oral treatment. Eur Urol Suppl 2003;2:2-9. (Pubitemid 37127536)
9. Engles CD, Hauser PJ, Abdullah SN, Culkin DJ, Hurst RE. Intravesical chondroitin sulfate inhibits recruitment of inflammatory cells in an acute acid damage "leaky bladder" model of cystitis. Urology 2012;79:483.e13-7.
10. Skene AJC. Diseases of the bladder and urethra in women. New York: William Wood; 1887. p. 167.
11. Forrest JB. Epidemiology and quality of life. J Reprod Med 2006;51(3 Suppl):227-33. (Pubitemid 43863297)
12. Koziol JA. Epidemiology of interstitial cystitis. Urol Clin North Am 1994;21:7-20. (Pubitemid 24032763)
13. Rosenberg MT, Newman DK, Page SA. Interstitial cystitis/painful bladder syndrome: symptom recognition is key to early identification, treatment. Cleve Clin J Med 2007;74(Suppl 3):S54-62.
14. Dell JR. Interstitial cystitis/painful bladder syndrome: appropriate diagnosis and management. J Womens Health (Larchmt) 2007;16:1181-7. (Pubitemid 47587339)
15. Parsons CL, Housley T, Schmidt JD, Lebow D. Treatment of interstitial cystitis with intravesical heparin. Br J Urol 1994;73:504-7. (Pubitemid 24190153)
16. Leppilahti M, Hellström P, Tammela TL. Effect of diagnostic hydrodistension and four intravesical hyaluronic acid instillations on bladder ICAM-1 intensity and association of ICAM-1 intensity with clinical response in patients with interstitial cystitis. Urology 2002;60:46-51. (Pubitemid 34722944)
17. Ahmad I, Sarath Krishna N, Meddings RN. Sequential hydrodistension and intravesical instillation of hyaluronic acid under general anaesthesia for treatment of refractory interstitial cystitis:a pilot study. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:543-6. (Pubitemid 351356445)
18. Shao Y, Shen ZJ, Rui WB, Zhou WL. Intravesical instillation of hyaluronic acid prolonged the effect of bladder hydrodistention in patients with severe interstitial cystitis. Urology 2010;75:547-50.
19. Morales A, Emerson L, Nickel JC, Lundie M. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. J Urol 1996;156:45-8. (Pubitemid 26187998)
20. Morales A, Emerson L, Nickel JC. Intravesical hyaluronic acid in the treatment of refractory interstitial cystitis. Urology 1997;49(5A Suppl):111-3.
21. Porru D, Campus G, Tudino D, Valdes E, Vespa A, Scarpa RM et al. Results of treatment of refractory interstitial cystitis with intravesical hyaluronic acid. Urol Int 1997;59:26-9. (Pubitemid 27421158)
22. Bade JJ, Laseur M, Nieuwenburg A, van der Weele LT, Mensink HJ. A placebo-controlled study of intravesical pentosanpolysulphate for the treatment of interstitial cystitis. Br J Urol 1997;79:168-71.
23. Kuo HC. Urodynamic results of intravesical heparin therapy for women with frequency urgency syndrome and interstitial cystitis. J Formos Med Assoc 2001;100:309-14.
24. Steinhoff G, Ittah B, Rowan S. The efficacy of chondroitin sulfate 0.2% in treating interstitial cystitis. Can J Urol 2002;9:1454-8.
25. Steinhoff G, Ittah B, Rowan S. The efficacy of intravesicular sterile sodium chondroitin sulfate 0.2% in potassium tested positive patients with interstitial cystitis. Adv Exp Med Biol 2003;539(Pt B):731-9.
26. Kallestrup EB, Jorgensen SS, Nordling J, Hald T. Treatment of interstitial cystitis with Cystistat:a hyaluronic acid product. Scand J Urol Nephrol 2005;39:143-7. (Pubitemid 40632330)
27. Gupta SK, Pidcock L, Parr NJ. The potassium sensitivity test:a predictor of treatment response in interstitial cystitis. BJU Int 2005;96:1063-6. (Pubitemid 41531415)
28. Daha LK, Riedl CR, Lazar D, Hohlbrugger G, Pflüger H. Do cystometric findings predict the results of intravesical hyaluronic acid in women with interstitial cystitis? Eur Urol 2005;47:393-7. (Pubitemid 40248868)
29. Theoharides TC, Kempuraj D, Vakali S, Sant GR. Treatment of refractory interstitial cystitis/painful bladder syndrome with CystoProtek - an oral multi-agent natural supplement. Can J Urol 2008;15:4410-4.
30. Cervigni M, Natale F, Nasta L, Padoa A, Voi RL, Porru D. A combined intravesical therapy with hyaluronic acid and chondroitin for refractory painful bladder syndrome/interstitial cystitis. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:943-7. (Pubitemid 351772626)
31. Riedl CR, Engelhardt PF, Daha KL, Morakis N, Pflüger H. Hyaluronan treatment of interstitial cystitis/painful bladder syndrome. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:717-21. (Pubitemid 351516951)
32. Porru D, Cervigni M, Nasta L, Natale F, Lo Voi R, Tinelli C et al. Results of endovesical hyaluronic acid/chondroitin sulfate in the treatment of Interstitial Cystitis/Painful Bladder Syndrome. Rev Recent Clin Trials 2008;3:126-9.
33. Daha LK, Lazar D, Simak R, Pflüger H. The effects of intravesical pentosanpolysulfate treatment on the symptoms of patients with bladder pain syndrome/interstitial cystitis: preliminary results. Int Urogynecol J Pelvic Floor Dysfunct 2008;19:987-90. (Pubitemid 351772633)
34. Nickel JC, Egerdie B, Downey J, Singh R, Skehan A, Carr L et al. A real-life multicentre clinical practice study to evaluate the efficacy and safety of intravesical chondroitin sulphate for the treatment of interstitial cystitis. BJU Int 2009;103:56-60.
35. Nickel JC, Egerdie RB, Steinhoff G, Palmer B, Hanno P. A multicenter, randomized, double-blind, parallel group pilot evaluation of the efficacy and safety of intravesical sodium chondroitin sulfate versus vehicle control in patients with interstitial cystitis/painful bladder syndrome. Urology 2010;76:804-9.
36. Engelhardt PF, Morakis N, Daha LK, Esterbauer B, Riedl CR. Long-term results of intravesical hyaluronan therapy in bladder pain syndrome/interstitial cystitis. Int Urogynecol J 2011;22:401-5.
37. Silverman JA, Schreiber HL 4th, Hooton TM, Hultgren SJ. From Physiology to Pharmacy:Developments in the Pathogenesis and Treatment of Recurrent Urinary Tract Infections. Curr Urol Rep 2013 [Epub ahead of print].
38. Naber KG, Bergman B, Bishop MC, Bjerklund-Johansen TE, Botto H, Lobel B et al.;Urinary Tract Infection (UTI) Association of Urology (EAU). EAU guidelines for the management of urinary and male genital tract infections. Urinary Tract Infection (UTI) Working Group of the Health Care Office (HCO) of the European Association of Urology (EAU). Eur Urol 2001;40:576-88. (Pubitemid 34289761)
39. Naber KG, Shaeffer AJ, Hynes CF, Matsumoto T, Shoskes DA, Bjerklund J. EAU/International Consultation on Urological Infections 2010. The Netherlands, European Association of Urology.
40. Parsons CL, Mulholland SG, Anwar H. Antibacterial activity of bladder surface mucin duplicated by exogenous glycosaminoglycan (heparin). Infect Immun 1979;24:552-7. (Pubitemid 9165491)
41. Grist M, Chakraborty J. Identification of a mucin layer in the urinary bladder. Urology 1994;44:26-33. (Pubitemid 124019713)
42. Parsons CL, Shrom SH, Hanno PM, Mulholland SG. Bladder surface mucin. Examination of possible mechanisms for its antibacterial effect. Invest Urol 1978;16:196-200. (Pubitemid 9163703)
43. Constantinides C, Manousakas T, Nikolopoulos P, Stanitsas A, Haritopoulos K, Giannopoulos A. Prevention of recurrent bacterial cystitis by intravesical administration of hyaluronic acid:a pilot study. BJU Int 2004;93:1262-6. (Pubitemid 38823949)
44. Lipovac M, Kurz C, Reithmayr F, Verhoeven HC, Huber JC, Imhof M. Prevention of recurrent bacterial urinary tract infections by intravesical instillation of hyaluronic acid. Int J Gynaecol Obstet 2007;96:192-5. (Pubitemid 46281918)
45. Damiano R, Quarto G, Bava I, Ucciero G, Palumbo MI, Autorino R et al. Prevention of recurrent urinary tract infections by intravesical administration of hyaluronic acid and chondroitin sulphate:a placebo-controlled randomised trial. Eur Urol 2011;59:645-51.
46. Cengiz N, Baskin E, Anarat R, Agras PI, Yildirim SV, Tiker F et al. Glycosaminoglycans in childhood urinary tract infections. Pediatr Nephrol 2005;20:937-9. (Pubitemid 40909264)
47. Manikandan R, Kumar S, Dorairajan LN. Hemorrhagic cystitis: a challenge to the urologist. Indian J Urol 2010;26:159-66.
48. Miodosky M, Abdul-Hai A, Tsirigotis P, Or R, Bitan M, Resnick IB et al. Treatment of post-hematopoietic stem cell transplantation hemorrhagic cystitis with intravesicular sodium hyaluronate. Bone Marrow Transplant 2006;38:507-11. (Pubitemid 44445356)
49. Cipe FE, Soygür T, Doǧu F, Erdoǧan O, Bozdoǧan G, Ikincioǧullari A. Late onset hemorrhagic cystitis in a hematopoietic stem cell recipient: treatment with intravesical hyaluronic acid. Pediatr Transplant 2010;14:E79-82.
50. Damiano R, Cicione A. The role of sodium hyaluronate and sodium chondroitin sulphate in the management of bladder disease. Ther Adv Urol 2011;3:223-32.
51. Drake MJ, Nixon PM, Crew JP. Drug-induced bladder and urinary disorders. Incidence, prevention and management. Drug Saf 1998;19:45-55. (Pubitemid 28353793)
52. Sommariva ML, Sandri SD, Guerrer CS. Treatment of acute iatrogenic cystitis secondary to bladder chemoimmuno-instillation or pelvic radiotherapy. Urologia 2010;77:187-92.
53. Samper Ots PM, Carrizosa CL, Rodriguez A, de Dios Saez J, Delgado JM, de Miguel MM et al. Vesical instillations of hyaluronic acid to reduce the acute vesical toxicity caused by high-dose brachytherapy do not affect the survival:a five-year follow-up study. Clin Transl Oncol 2009;11:828-34.
54. Hazewinkel MH, Stalpers LJ, Dijkgraaf MG, Roovers JP. Prophylactic vesical instillations with 0.2% chondroitin sulfate may reduce symptoms of acute radiation cystitis in patients undergoing radiotherapy for gynecological malignancies. Int Urogynecol J 2011;22:725-30.
55. Wein AJ, Rovner ES. Definition and epidemiology of overactive bladder. Urology 2002;60(5 Suppl 1):7-12;discussion 12.
56. Stewart WF, Van Rooyen JB, Cundiff GW, Abrams P, Herzog AR, Corey R et al. Prevalence and burden of overactive bladder in the United States. World J Urol 2003;20:327-36. (Pubitemid 44175300)
57. Milsom I, Abrams P, Cardozo L, Roberts RG, Thüroff J, Wein AJ. How widespread are the symptoms of an overactive bladder and how are they managed? A population-based prevalence study. BJU Int 2001;87:760-6. (Pubitemid 34204313)
58. Gauruder-Burmester A, Wildt B, Tunn R. Treatment of overactive bladder with sodium chondroitin sulphate. Zentralbl Gynakol 2006;128:336-40. (Pubitemid 46102230)
59. Gauruder-Burmester A, Popken G. Follow-up at 24 months after treatment of overactive bladder with 0.2% sodium chondroitin sulfate. Aktuelle Urol 2009;40:355-9.
60. Arance I, Ramón de Fata F, Angulo JC, González-Enguita C, Errando C, Cozar JM et al. Available evidence about efficacy of different restoring agents of glycosaminoglycans for intravesical use in interstitial cystitis. Actas Urol Esp 2013;37:92-9.